Table of Content

1. Overview

1.1 Urea Cycle
1.2 Process of Urea Cycle
1.3 Urea Cycle Disorder (UCD)
1.4 Types of UCDs and Their Management
1.5 Diagnosis and Treatment of UCD


2. The U.S. Market Analysis

2.1 The U.S. Total UCD Population Forecast
2.2 The U.S. Existing and New UCD Population Forecast
2.3 The U.S. Diagnosed UCD Population Forecast
2.4 The U.S. UCD Drug Market
2.4.1 The U.S. Ravicti Revenue
2.4.2 The U.S. Ravicti Revenue Forecast
2.4.3 The U.S KB195 Revenue Forecast
2.4.4 The U.S. UCD Population Treated with KB195 Forecast


3. Europe Market Analysis

3.1 Europe UCD Population Forecast
3.2 Europe Existing and New UCD Population Forecast
3.3 Europe Diagnosed UCD Population Forecast
3.4 Europe UCD Drug Market
3.4.1 Europe KB195 Revenue Forecast
3.4.2 Europe UCD Population Treated with KB195 Forecast


4. Market Dynamics

4.1 Growth Drivers
4.1.1 Increasing Healthcare Expenditure in the U.S.
4.1.2 Rise in Pharmaceutical R&D Expenditures in the U.S.
4.1.3 Collaboration of Pharmaceutical Companies with Research Institutes

4.2 Key Trends and Development
4.2.1 Shifts in the Newborn Population in the U.S. and Europe
4.2.2 Upcoming Launches of Anti-UCD Drugs
4.2.3 Development of Orphan Drugs for Urea Cycle Disorder

4.3 Challenges
4.3.1 Less Definitive Treatment Options
4.3.2 High Healthcare and Medical Costs
4.3.3 Stringent Medical Regulations


5. Competitive Landscape

5.1 Key Players – Drugs Pipeline in the Urea Cycle Disorder Space
5.2 Key Players – Revenue Comparison
5.3 Key Players – Market Capital Comparison


6. Company Profiles

6.1 Horizon Pharma Plc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies

6.2 Ultragenyx Pharmaceuticals Inc.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies

6.3 Aeglea Bio Therapeutics
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies

6.4 Synlogix
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
 



List of Figures



Urea Cycle
The U.S Total UCD Population Forecast (2019-2023)
The U.S Existing and New UCD Population Forecast (2019-2023)
The U.S Diagnosed UCD Population Forecast (2019-2023)
The U.S Ravicti Revenue (2014-2018)
The U.S Ravicti Revenue Forecast (2019-2023)
The U.S KB195 Revenue Forecast (2022-2026)
The U.S. UCD Population Treated with KB195 Forecast (2022-2026)
Europe UCD Population Forecast (2019-2023)
Europe Existing and New UCD Population Forecast (2019-2022)
Europe Diagnosed UCD Population Forecast (2019-2023)
Europe KB195 Revenue Forecast (2023-2027)
Europe UCD Population Treated with KB195 Forecast (2023-2027)
The U.S. Healthcare Expenditure per Capita (2014-2018)
Pharmaceutical R&D Expenditures in the U.S. (2014-2018)
The U.S and Europe Newborn Population Forecast (2019-2023)
Key Players – Market Capital Comparison
Horizon Pharma Plc. Revenue by Segment (2018)
Horizon Pharma Plc. Revenue and Net Loss (2014-2018)
Horizon Pharma Plc. R&D Expenditure (2016-2018)
Horizon Pharma Plc. Advertising Expenditure (2016-2018)
Ultragenyx Pharmaceuticals Revenue by Segment (2018)
Ultragenyx Pharmaceuticals Revenue and Net Loss (2014-2018)
Ultragenyx Pharmaceuticals R&D Expenditure (2016-2018)
Aeglea Bio Therapeutics Revenue and Net Loss (2014-2018)
Aeglea Bio Therapeutics R&D Expenditure (2016-2018)
Synlogix Revenue and Net Loss (2014-2018)
Synlogix R&D Expenditure (2016-2018)

List of Tables



Types of UCDs and Their Management
Upcoming Launches of Anti-UCD Drugs
Regulations and Policies for Orphan Drugs
Key Players – Product Pipeline in the Urea Cycle Disorder Space
Key Players – Revenue Comparison (2018)
Aeglea Bio Therapeutics Drugs Pipeline Overview (2018)
Synlogix Drugs Pipeline Overview (2018)